Dr Liz Lightstone, PhD, FRCP

Dr Liz Lightstone, PhD, FRCP

Imperial College London,
United Kingdom

Liz Lightstone is a Reader in Renal Medicine in the Division of Immunology and Inflammation, Department of Medicine, Imperial College London, and an Honorary Consultant Renal Physician in the Imperial College Healthcare NHS Trust Renal and Transplant Centre (ICHNT RTC). After an undergraduate degree at Cambridge, she graduated in medicine from the University of London in 1983 and trained in nephrology at the Royal Postgraduate Medical School. She won a Medical Research Council (MRC) Training Fellowship in 1988 and undertook a PhD in immunology at University College London. This was followed by a MRC Clinician Scientist Fellowship at the Royal Postgraduate Medical School. She was appointed Senior Lecturer and Honorary Consultant Physician in 1995.

Dr Lightstone has major roles in undergraduate and postgraduate medicine at Imperial College, in particular as Director of the Academic Foundation programme within the North West Thames Foundation School. She is a member of the LUPUS UK Peer Review Panel. She was an elected member of the UK Renal Association Executive and remains active in the Renal Association Programme Planning group and Equal Opportunities Committee. She is on the EU executive of the Lupus Nephritis Trials Network, was an author on the 2012 European League Against Rheumatism (EULAR) recommendations for the treatment of lupus nephritis and regularly advises on the design of trials in lupus nephritis.

Dr Lightstone’s research is now focused on Lupus Nephritis as well as Pregnancy in Women with Kidney Disease. Together with colleagues in the ICHNT RTC, she pioneered the use of steroid-minimising regimens in lupus nephritis. She is Chief Investigator on the planned international multicentre randomised RITUXILUP trial funded by Arthritis Research UK. She is particularly interested in developing better ways of predicting outcomes, not least by improving adherence to therapy. To this end she has established a new assay of hydroxychloroquine levels as a marker of adherence to therapy. She is also working on identifying urine biomarkers and histological features that better predict the outcome of lupus nephritis. She is the inaugural National Coordinator of the newly established Pregnancy and Chronic Kidney Disease —Rare Disease Group and has pioneered the use of tacrolimus in the treatment of lupus nephritis in pregnancy.

Her main clinical interests are in lupus nephritis (she jointly manages a combined renal/rheumatology lupus clinic following over 300 patients with lupus nephritis) and the management of women with kidney disease in pregnancy—she established and runs a renal obstetric clinic and a preconception counselling clinic.

Disclosures

Consultant/Advisor: Anthera, Aspreva Pharmaceuticals, Biogen Idec, EMD Serono, Genentech, GlaxoSmithKline, MedImmune, Merck, Roche, Teva, Vifor

Secretariat
Lupus Academy Foundation
Maasdijk 409
4264 AS Veen
The Netherlands
Tel: +31 (0) 416 693 925
Email: secretariat@lupus-academy.org